Presentation is loading. Please wait.

Presentation is loading. Please wait.

Presented By Shin Fujita at 2016 ASCO Annual Meeting

Published byNorma Booth Modified over 8 years ago

Similar presentations

Presentation on theme: "Presented By Shin Fujita at 2016 ASCO Annual Meeting"— Presentation transcript:

1 Presented By Shin Fujita at 2016 ASCO Annual Meeting
A randomized trial comparing mesorectal excision with or without lateral lymph node dissection for clinical stage II, III lower rectal cancer: Primary endpoint analysis of Japan Clinical Oncology Group Study JCOG0212 Presented By Shin Fujita at 2016 ASCO Annual Meeting

2 Presented By Shin Fujita at 2016 ASCO Annual Meeting
Background Presented By Shin Fujita at 2016 ASCO Annual Meeting

3 Presented By Shin Fujita at 2016 ASCO Annual Meeting
Objective Presented By Shin Fujita at 2016 ASCO Annual Meeting

4 Presented By Shin Fujita at 2016 ASCO Annual Meeting
Study schema Presented By Shin Fujita at 2016 ASCO Annual Meeting

5 Key eligibility criteria
Presented By Shin Fujita at 2016 ASCO Annual Meeting

6 Presented By Shin Fujita at 2016 ASCO Annual Meeting
Endpoints Presented By Shin Fujita at 2016 ASCO Annual Meeting

7 Summary of operative details and safety
Presented By Shin Fujita at 2016 ASCO Annual Meeting

8 Statistical consideration
Presented By Shin Fujita at 2016 ASCO Annual Meeting

9 Presented By Shin Fujita at 2016 ASCO Annual Meeting
CONSORT diagram Presented By Shin Fujita at 2016 ASCO Annual Meeting

10 Patient Characteristics
Presented By Shin Fujita at 2016 ASCO Annual Meeting

11 Presented By Shin Fujita at 2016 ASCO Annual Meeting
Slide 11 Presented By Shin Fujita at 2016 ASCO Annual Meeting

12 Relapse-free survival [All randomized pts]
Presented By Shin Fujita at 2016 ASCO Annual Meeting

13 Relapse-free survival [All eligible pts]
Presented By Shin Fujita at 2016 ASCO Annual Meeting

14 Overall survival [All randomized pts]
Presented By Shin Fujita at 2016 ASCO Annual Meeting

15 Local-recurrence free survival [All randomized pts]
Presented By Shin Fujita at 2016 ASCO Annual Meeting

16 Classification of local recurrence sites
Presented By Shin Fujita at 2016 ASCO Annual Meeting

17 Local recurrence sites
Presented By Shin Fujita at 2016 ASCO Annual Meeting

18 Subgroup analysis of RFS
Presented By Shin Fujita at 2016 ASCO Annual Meeting

19 Presented By Shin Fujita at 2016 ASCO Annual Meeting
Conclusions Presented By Shin Fujita at 2016 ASCO Annual Meeting

20 Presented By Shin Fujita at 2016 ASCO Annual Meeting
Acknowledgement Presented By Shin Fujita at 2016 ASCO Annual Meeting

Download ppt "Presented By Shin Fujita at 2016 ASCO Annual Meeting"

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.

Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.
First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.

516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.

Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.
Presented By Patrick Wen at 2014 ASCO Annual Meeting

Presented By Patrick Wen at 2014 ASCO Annual Meeting
Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.
Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.

Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.

The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.
Japanese Approach to colon cancer and the Outcome Dep. of Surgical Oncology Tokyo Medical and Dental University Kenichi Sugihara.

Japanese Approach to colon cancer and the Outcome Dep. of Surgical Oncology Tokyo Medical and Dental University Kenichi Sugihara.
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
Title of the Paper Your Name Critical Care Medicine School of Medicine University of Pittsburgh.

Title of the Paper Your Name Critical Care Medicine School of Medicine University of Pittsburgh.
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.

Similar presentations

Ads by Google